The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis.
Re-TURBT
SARS-CoV-2
bladder cancer
intravesical BCG
trans-urethral resection of bladder tumor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
21 Oct 2021
21 Oct 2021
Historique:
received:
30
08
2021
revised:
14
10
2021
accepted:
18
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
14
11
2021
Statut:
epublish
Résumé
To investigate the impact of COVID-19 outbreak on the diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC). A retrospective analysis was performed using an Italian multi-institutional database of TURBT patients with high-risk urothelial NMIBC between January 2019 and February 2021, followed by Re-TURBT and/or adjuvant intravesical BCG. A total of 2591 patients from 27 institutions with primary TURBT were included. Of these, 1534 (59.2%) and 1056 (40.8%) underwent TURBT before and during the COVID-19 outbreak, respectively. Time between diagnosis and TURBT was significantly longer during the COVID-19 period (65 vs. 52 days, The COVID-19 pandemic represented an unprecedented challenge to our health system. Our study did not show significant differences in TURBT quality. However, a delay in treatment schedule and disease management was observed. Investigation of the oncological impacts of those differences should be advocated.
Sections du résumé
BACKGROUND
BACKGROUND
To investigate the impact of COVID-19 outbreak on the diagnosis and treatment of non-muscle invasive bladder cancer (NMIBC).
METHODS
METHODS
A retrospective analysis was performed using an Italian multi-institutional database of TURBT patients with high-risk urothelial NMIBC between January 2019 and February 2021, followed by Re-TURBT and/or adjuvant intravesical BCG.
RESULTS
RESULTS
A total of 2591 patients from 27 institutions with primary TURBT were included. Of these, 1534 (59.2%) and 1056 (40.8%) underwent TURBT before and during the COVID-19 outbreak, respectively. Time between diagnosis and TURBT was significantly longer during the COVID-19 period (65 vs. 52 days,
CONCLUSIONS
CONCLUSIONS
The COVID-19 pandemic represented an unprecedented challenge to our health system. Our study did not show significant differences in TURBT quality. However, a delay in treatment schedule and disease management was observed. Investigation of the oncological impacts of those differences should be advocated.
Identifiants
pubmed: 34771440
pii: cancers13215276
doi: 10.3390/cancers13215276
pmc: PMC8582553
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur Urol. 2013 Mar;63(3):462-72
pubmed: 23141049
Oncology. 2020;98(10):743-747
pubmed: 32570240
Cent European J Urol. 2020;73(2):152-159
pubmed: 32782834
World J Urol. 2014 Apr;32(2):475-9
pubmed: 23455886
BMC Cancer. 2019 Nov 6;19(1):1054
pubmed: 31694589
Cancer Manag Res. 2021 Jul 29;13:5875-5887
pubmed: 34349561
Socioecon Plann Sci. 2021 Jul 3;:101120
pubmed: 34248212
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Pers Med. 2021 Mar 23;11(3):
pubmed: 33806972
PeerJ. 2021 Jun 29;9:e11603
pubmed: 34249495
Nat Rev Urol. 2021 Apr;18(4):185-187
pubmed: 33335321
Eur Urol. 2020 Jul;78(1):e18-e20
pubmed: 32360050
Urologe A. 1994 Nov;33(6):532-5
pubmed: 7817452
Minerva Urol Nefrol. 2020 Jun;72(3):369-375
pubmed: 32202401
J Laparoendosc Adv Surg Tech A. 2020 Aug;30(8):915-918
pubmed: 32498612
Eur Urol. 2019 Nov;76(5):639-657
pubmed: 31443960
Urol Int. 2018;101(1):7-15
pubmed: 29975950
BJU Int. 2002 Jun;89(9):868-78
pubmed: 12010230
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
Cancers (Basel). 2020 Jun 10;12(6):
pubmed: 32531948
Urologia. 2015 Jan-Mar;82(1):58-70
pubmed: 25744706
Curr Opin Urol. 2020 May;30(3):365-369
pubmed: 32141939
Head Neck. 2021 Nov;43(11):3493-3497
pubmed: 34494330
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Nat Rev Urol. 2020 May;17(5):251-253
pubmed: 32203310
Eur Urol Focus. 2020 Sep 15;6(5):1120-1123
pubmed: 32522412
Cancer Cell. 2020 Dec 14;38(6):769-770
pubmed: 33176161
BJU Int. 2019 Mar;123(3):401-410
pubmed: 30537407
Eur Urol. 2021 Jan;79(1):62-79
pubmed: 32593530
Arch Med Sci. 2020 Aug 25;17(5):1262-1276
pubmed: 34522255
Can J Urol. 2006 Jun;13 Suppl 3:62-4
pubmed: 16818014
Eur Urol. 2020 Jul;78(1):21-28
pubmed: 32376137
Front Surg. 2020 Nov 24;7:563006
pubmed: 33330604